2021
Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
HYZA, M., P. SILHAN, E. CESKOVA, T. SKRONT, I. KACIROVA et. al.Základní údaje
Originální název
Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
Autoři
HYZA, M., P. SILHAN, E. CESKOVA, T. SKRONT, I. KACIROVA, R. URINOVSKA a M. GRUNDMANN
Vydání
Neuropsychiatric Disease and Treatment, New Zealand, Dove Medical Press, 2021, 1176-6328
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.154 v roce 2013
UT WoS
000641063300001
Klíčová slova anglicky
therapeutic drug monitoring; antipsychotics; psychotic disorders; schizophrenia
Štítky
Změněno: 7. 12. 2021 13:00, Bc. Hana Vladíková, BBA
Anotace
V originále
Purpose: Antipsychotic efficacy in schizophrenia depends on its availability in the body. Although therapeutic outcomes remain still far from satisfactory, therapeutic drug monitoring not a common part of clinical practice during treatment with long-acting injectable antipsychotics (LAI AP). The real effectiveness of LAI AP is thus uncertain. Patients and Methods: We made a retrospective evaluation of plasma levels of LAI AP. Collection of blood samples was performed just before the drug application and one week later. Forty patients with a stabilized clinical condition and steady-state plasma levels were included. Results: In the observed cohort of patients, flupentixol decanoate (n = 23) was the most often used drug, followed by fluphenazine decanoate (n = 7), haloperidol decanoate (n = 5), paliperidone palmitate (n = 3), and risperidone microspheres (n = 2). Just 5 of 40 patients were treated with a monotherapy. In the period before the application, 60% of the patients did not reach the therapeutic reference range (TRR) and 20% of the patients had an undetectable plasma level. At the time of collection of the second blood samples performed after 7 days, 24% of the patients were under the TRR. Conclusion: We have found a surprisingly high incidence of plasma levels under the TRR patients treated with LAI AP. Notwithstanding individual variability in pharmacokinetics, seems that LAI AP may be underdosed in usual clinical practice.
Návaznosti
90128, velká výzkumná infrastruktura |
|